Download PDF
Semin Respir Crit Care Med 2018; 39(04): 465-470
DOI: 10.1055/s-0038-1669914
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Antineutrophil Cytoplasmic Antibody–Associated Lung Fibrosis

Raphael Borie
1   Assistance Publique Hôpitaux de Paris, Bichat Hospital, Rare Pulmonary Diseases Reference Center, Paris, France
2   Institut National de la Recherche Médicale, Unit 1152, DHU FIRE, Paris Diderot University, Paris, France
,
Bruno Crestani
1   Assistance Publique Hôpitaux de Paris, Bichat Hospital, Rare Pulmonary Diseases Reference Center, Paris, France
2   Institut National de la Recherche Médicale, Unit 1152, DHU FIRE, Paris Diderot University, Paris, France
› Author Affiliations
Further Information

Publication History

Publication Date:
07 November 2018 (online)

    Permissions and Reprints

Abstract

Pulmonary fibrosis is observed in a substantial number of patients with ANCA-associated vasculitis (AAV), 15% in a recent German series, and may be more frequent in Asian populations. ANCA are usually of anti-MPO specificity and microscopic polyangiitis is the most frequent vasculitis. Pulmonary fibrosis may increase the risk of death in patients with AAV. Treatment for AAV in patients with lung fibrosis should follow the international guidelines for vasculitis. The role of anti-fibrotic drugs (pirfenidone, nintedanib) in this condition is still unknown. Pulmonary fibrosis precedes the diagnosis of AAV or is diagnosed concomitantly in most of the cases. Interestingly, 4% to 35% of patients with pulmonary fibrosis are ANCA-positive, but only 7% to 23% of the patients with pulmonary fibrosis and anti-MPO will develop AAV during follow-up. ANCA positivity may be detected in idiopathic or non idiopathic pulmonary fibrosis. In the absence of vasculitis, the detection of ANCA does not influence the diagnostic work-up of patients with lung fibrosis. If an Idiopathic Pulmonary Fibrosis diagnosis is considered, an anti-fibrotic therapy should be considered, according to local and international guidelines.

Keywords

idiopathic pulmonary fibrosis - STING - COPA - usual interstitial pneumonia - microscopic polyangiitis - myeloperoxidase
 

  • References

  • 1 Raghu G, Collard HR, Egan JJ. , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (06) 788-824
    CrossrefPubMedGoogle Scholar
  • 2 Travis WD, Hoffman GS, Leavitt RY, Pass HI, Fauci AS. Surgical pathology of the lung in Wegener's granulomatosis. Review of 87 open lung biopsies from 67 patients. Am J Surg Pathol 1991; 15 (04) 315-333
    CrossrefPubMedGoogle Scholar
  • 3 Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med 2018; 378 (19) 1811-1823
    CrossrefPubMedGoogle Scholar
  • 4 Molyneaux PL, Willis-Owen SAG, Cox MJ. , et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2017; 195 (12) 1640-1650
    CrossrefPubMedGoogle Scholar
  • 5 Selman M, López-Otín C, Pardo A. Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir J 2016; 48 (02) 538-552
    CrossrefPubMedGoogle Scholar
  • 6 Birnbaum J, Danoff S, Askin FB, Stone JH. Microscopic polyangiitis presenting as a “pulmonary-muscle” syndrome: is subclinical alveolar hemorrhage the mechanism of pulmonary fibrosis?. Arthritis Rheum 2007; 56 (06) 2065-2071
    CrossrefPubMedGoogle Scholar
  • 7 Kay JM, Edwards FR. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol 1973; 111 (04) 239-245
    CrossrefPubMedGoogle Scholar
  • 8 Le Clainche L, Le Bourgeois M, Fauroux B. , et al. Long-term outcome of idiopathic pulmonary hemosiderosis in children. Medicine (Baltimore) 2000; 79 (05) 318-326
    PubMedGoogle Scholar
  • 9 Chintagari NR, Jana S, Alayash AI. Oxidized ferric and ferryl forms of hemoglobin trigger mitochondrial dysfunction and injury in alveolar type I cells. Am J Respir Cell Mol Biol 2016; 55 (02) 288-298
    CrossrefPubMedGoogle Scholar
  • 10 Comarmond C, Crestani B, Tazi A. , et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014; 93 (24) 340-349
    PubMedGoogle Scholar
  • 11 Foulon G, Delaval P, Valeyre D. , et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008; 102 (10) 1392-1398
    CrossrefPubMedGoogle Scholar
  • 12 Guilpain P, Chéreau C, Goulvestre C. , et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011; 37 (06) 1503-1513
    CrossrefPubMedGoogle Scholar
  • 13 Foucher P, Heeringa P, Petersen AH. , et al. Antimyeloperoxidase-associated lung disease. An experimental model. Am J Respir Crit Care Med 1999; 160 (03) 987-994
    CrossrefPubMedGoogle Scholar
  • 14 Lucattelli M, Bartalesi B, Cavarra E. , et al. Is neutrophil elastase the missing link between emphysema and fibrosis? Evidence from two mouse models. Respir Res 2005; 6: 83
    CrossrefPubMedGoogle Scholar
  • 15 Meyer KC, Raghu G, Baughman RP. , et al; American Thoracic Society Committee on BAL in Interstitial Lung Disease. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012; 185 (09) 1004-1014
    CrossrefPubMedGoogle Scholar
  • 16 Turner-Warwick M, Doniach D. Auto-antibody studies in interstitial pulmonary fibrosis. BMJ 1965; 1 (5439): 886-891
    CrossrefPubMedGoogle Scholar
  • 17 Turner-Warwick M, Parkes WR. Circulating rheumatoid and antinuclear factors in asbestos workers. BMJ 1970; 3 (5721): 492-495
    CrossrefPubMedGoogle Scholar
  • 18 Soutar CA, Turner-Warwick M, Parkes WR. Circulating antinuclear antibody and rheumatoid factor in coal pneumoconiosis. BMJ 1974; 3 (5924): 145-147
    CrossrefPubMedGoogle Scholar
  • 19 Holgate ST, Haslam P, Turner-Warwick M. The significance of antinuclear and DNA antibodies in cryptogenic fibrosing alveolitis. Thorax 1983; 38 (01) 67-70
    CrossrefPubMedGoogle Scholar
  • 20 Kang BH, Park JK, Roh JH. , et al. Clinical significance of serum autoantibodies in idiopathic interstitial pneumonia. J Korean Med Sci 2013; 28 (05) 731-737
    CrossrefPubMedGoogle Scholar
  • 21 Lee JS, Kim EJ, Lynch KL. , et al. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med 2013; 107 (02) 249-255
    CrossrefPubMedGoogle Scholar
  • 22 Hoyne GF, Elliott H, Mutsaers SE, Prêle CM. Idiopathic pulmonary fibrosis and a role for autoimmunity. Immunol Cell Biol 2017; 95 (07) 577-583
    CrossrefPubMedGoogle Scholar
  • 23 Herazo-Maya JD, Noth I, Duncan SR. , et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5 (205) 205ra136
    CrossrefPubMedGoogle Scholar
  • 24 Herazo-Maya JD, Sun J, Molyneaux PL. , et al. Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir Med 2017; 5 (11) 857-868
    CrossrefPubMedGoogle Scholar
  • 25 Marchal-Sommé J, Uzunhan Y, Marchand-Adam S. , et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006; 176 (10) 5735-5739
    CrossrefPubMedGoogle Scholar
  • 26 Marchal-Sommé J, Uzunhan Y, Marchand-Adam S. , et al. Dendritic cells accumulate in human fibrotic interstitial lung disease. Am J Respir Crit Care Med 2007; 176 (10) 1007-1014
    CrossrefPubMedGoogle Scholar
  • 27 Schiller HB, Mayr CH, Leuschner G. , et al. Deep proteome profiling reveals common prevalence of MZB1-positive plasma B cells in human lung and skin fibrosis. Am J Respir Crit Care Med 2017; 196 (10) 1298-1310
    CrossrefPubMedGoogle Scholar
  • 28 Feghali-Bostwick CA, Tsai CG, Valentine VG. , et al. Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J Immunol 2007; 179 (04) 2592-2599
    CrossrefPubMedGoogle Scholar
  • 29 Groot Kormelink T, Pardo A, Knipping K. , et al. Immunoglobulin free light chains are increased in hypersensitivity pneumonitis and idiopathic pulmonary fibrosis. PLoS One 2011; 6 (09) e25392
    CrossrefPubMedGoogle Scholar
  • 30 Kotsianidis I, Nakou E, Bouchliou I. , et al. Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179 (12) 1121-1130
    CrossrefPubMedGoogle Scholar
  • 31 Gereke M, Jung S, Buer J, Bruder D. Alveolar type II epithelial cells present antigen to CD4(+) T cells and induce Foxp3(+) regulatory T cells. Am J Respir Crit Care Med 2009; 179 (05) 344-355
    CrossrefPubMedGoogle Scholar
  • 32 Dall'Aglio PP, Pesci A, Bertorelli G, Brianti E, Scarpa S. Study of immune complexes in bronchoalveolar lavage fluids. Respiration 1988; 54 (Suppl. 01) 36-41
    CrossrefPubMedGoogle Scholar
  • 33 Dobashi N, Fujita J, Murota M. , et al. Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. Lung 2000; 178 (03) 171-179
    CrossrefPubMedGoogle Scholar
  • 34 Kahloon RA, Xue J, Bhargava A. , et al. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013; 187 (07) 768-775
    CrossrefPubMedGoogle Scholar
  • 35 Wallace WA, Roberts SN, Caldwell H. , et al. Circulating antibodies to lung protein(s) in patients with cryptogenic fibrosing alveolitis. Thorax 1994; 49 (03) 218-224
    CrossrefPubMedGoogle Scholar
  • 36 Wallace WA, Schofield JA, Lamb D, Howie SE. Localisation of a pulmonary autoantigen in cryptogenic fibrosing alveolitis. Thorax 1994; 49 (11) 1139-1145
    CrossrefPubMedGoogle Scholar
  • 37 Dobashi N, Fujita J, Ohtsuki Y. , et al. Detection of anti-cytokeratin 8 antibody in the serum of patients with cryptogenic fibrosing alveolitis and pulmonary fibrosis associated with collagen vascular disorders. Thorax 1998; 53 (11) 969-974
    CrossrefPubMedGoogle Scholar
  • 38 Fujita J, Dobashi N, Ohtsuki Y. , et al. Elevation of anti-cytokeratin 19 antibody in sera of the patients with idiopathic pulmonary fibrosis and pulmonary fibrosis associated with collagen vascular disorders. Lung 1999; 177 (05) 311-319
    CrossrefPubMedGoogle Scholar
  • 39 Yang Y, Fujita J, Bandoh S. , et al. Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Clin Exp Immunol 2002; 128 (01) 169-174
    CrossrefPubMedGoogle Scholar
  • 40 Kurosu K, Takiguchi Y, Okada O. , et al. Identification of annexin 1 as a novel autoantigen in acute exacerbation of idiopathic pulmonary fibrosis. J Immunol 2008; 181 (01) 756-767
    CrossrefPubMedGoogle Scholar
  • 41 Fahim A, Chong MC, Crooks MG, Hart SP. Idiopathic pulmonary fibrosis is associated with circulating antiepithelial antibodies. Lung 2012; 190 (04) 451-458
    CrossrefPubMedGoogle Scholar
  • 42 Beltramo G, Thabut G, Peron N. , et al. Anti-parietal cell autoimmunity is associated with an accelerated decline of lung function in IPF patients. Respir Med 2018; 135: 15-21
    CrossrefPubMedGoogle Scholar
  • 43 Taillé C, Grootenboer-Mignot S, Boursier C. , et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183 (06) 759-766
    CrossrefPubMedGoogle Scholar
  • 44 Watad A, Bragazzi NL, Adawi M. , et al. Autoimmunity in the elderly: insights from basic science and clinics - a mini-review. Gerontology 2017; 63 (06) 515-523
    CrossrefPubMedGoogle Scholar
  • 45 Borie R, Kannengiesser C, Sicre de Fontbrune F, Gouya L, Nathan N, Crestani B. Management of suspected monogenic lung fibrosis in a specialised centre. Eur Respir Rev 2017; 26 (144) xx-xx
    PubMedGoogle Scholar
  • 46 Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol 2016; 3 (03) 122-133
    PubMedGoogle Scholar
  • 47 Hoffman TW, van Moorsel CHM, Borie R, Crestani B. Pulmonary phenotypes associated with genetic variation in telomere-related genes. Curr Opin Pulm Med 2018; 24 (03) 269-280
    PubMedGoogle Scholar
  • 48 Borie R, Tabèze L, Thabut G. , et al. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J 2016; 48 (06) 1721-1731
    CrossrefPubMedGoogle Scholar
  • 49 Juge P-A, Borie R, Kannengiesser C. , et al; FREX consortium. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017; 49 (05) 1602314
    CrossrefPubMedGoogle Scholar
  • 50 Borie R, Kannengiesser C, Sicre de Fontbrune F. , et al. Pneumocystosis revealing immunodeficiency secondary to TERC mutation. Eur Respir J 2017; 50 (05) 1701443
    CrossrefPubMedGoogle Scholar
  • 51 Arulkumaran N, Periselneris N, Gaskin G. , et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011; 50 (11) 2035-2043
    CrossrefPubMedGoogle Scholar
  • 52 Schirmer JH, Wright MN, Herrmann K. , et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (Wegener's) is a clinically distinct subset of ANCA-associated vasculitis: a retrospective analysis of 315 patients from a German Vasculitis Referral Center. Arthritis Rheumatol 2016; 68 (12) 2953-2963
    PubMedGoogle Scholar
  • 53 Schirmer JH, Wright MN, Vonthein R. , et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford) 2016; 55 (01) 71-79
    CrossrefPubMedGoogle Scholar
  • 54 Tzelepis GE, Kokosi M, Tzioufas A. , et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36 (01) 116-121
    CrossrefPubMedGoogle Scholar
  • 55 Huang H, Wang YX, Jiang CG. , et al. A retrospective study of microscopic polyangiitis patients presenting with pulmonary fibrosis in China. BMC Pulm Med 2014; 14: 8
    CrossrefPubMedGoogle Scholar
  • 56 Furuta S, Chaudhry AN, Hamano Y. , et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 2014; 41 (02) 325-333
    PubMedGoogle Scholar
  • 57 Fischer A, Antoniou KM, Brown KK. , et al; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46 (04) 976-987
    CrossrefPubMedGoogle Scholar
  • 58 Kono M, Nakamura Y, Enomoto N. , et al. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One 2014; 9 (04) e94775
    CrossrefPubMedGoogle Scholar
  • 59 Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res 2015; 2 (01) e000058
    PubMedGoogle Scholar
  • 60 Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration 2009; 77 (04) 407-415
    CrossrefPubMedGoogle Scholar
  • 61 Hozumi H, Enomoto N, Oyama Y. , et al. Clinical implication of proteinase-3-antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias. Lung 2016; 194 (02) 235-242
    CrossrefPubMedGoogle Scholar
  • 62 Raghu G, Anstrom KJ, King Jr TE, Lasky JA, Martinez FJ. ; Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366 (21) 1968-1977
    CrossrefPubMedGoogle Scholar
  • 63 Ando M, Miyazaki E, Ishii T. , et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangiitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013; 107 (04) 608-615
    CrossrefPubMedGoogle Scholar
  • 64 Hosoda C, Baba T, Hagiwara E. , et al. Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis. Respirology 2016; 21 (05) 920-926
    CrossrefPubMedGoogle Scholar
  • 65 Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis 1994; 53 (01) 24-29
    CrossrefPubMedGoogle Scholar
  • 66 Raghu G, Rochwerg B, Zhang Y. , et al; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192 (02) e3-e19
    CrossrefPubMedGoogle Scholar
  • 67 Cottin V, Crestani B, Cadranel J. , et al. French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version. Rev Mal Respir 2017; 34 (08) 900-968
    CrossrefPubMedGoogle Scholar
  • 68 Liu Y, Jesus AA, Marrero B. , et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371 (06) 507-518
    CrossrefPubMedGoogle Scholar
  • 69 Picard C, Thouvenin G, Kannengiesser C. , et al. Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 mutation). Chest 2016; 150 (03) e65-e71
    CrossrefPubMedGoogle Scholar
  • 70 Seo J, Kang J-A, Suh DI. , et al. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173. J Allergy Clin Immunol 2017; 139 (04) 1396-1399.e12
    CrossrefPubMedGoogle Scholar
  • 71 Frémond M-L, Rodero MP, Jeremiah N. , et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol 2016; 138 (06) 1752-1755
    CrossrefPubMedGoogle Scholar
  • 72 Watkin LB, Jessen B, Wiszniewski W. , et al; Baylor-Hopkins Center for Mendelian Genomics. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat Genet 2015; 47 (06) 654-660
    CrossrefPubMedGoogle Scholar
  • 73 Volpi S, Tsui J, Mariani M. , et al. Type I interferon pathway activation in COPA syndrome. Clin Immunol 2018; 187: 33-36
    CrossrefPubMedGoogle Scholar
  • 74 Vece TJ, Watkin LB, Nicholas S. , et al. Copa syndrome: a novel autosomal dominant immune dysregulatory disease. J Clin Immunol 2016; 36 (04) 377-387
    CrossrefPubMedGoogle Scholar
  • 75 Tsui JL, Estrada OA, Deng Z. , et al. Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Res 2018; 4 (02) xx-xx
    PubMedGoogle Scholar
  • 76 Noorelahi R, Perez G, Otero HJ. Imaging findings of Copa syndrome in a 12-year-old boy. Pediatr Radiol 2018; 48 (02) 279-282
    CrossrefPubMedGoogle Scholar